Build a multimodal big data platform and a multi-omics high-throughput detection system to screen and validate the efficacy and toxicity biomarkers of radioimmunotherapy combined with other treatments

INTERVENTION: Trial group:Trial group: Pirfenidone capsules + basic treatment; Pirfenidone capsules 100mg per capsule. Week 1: oral 2 capsules per dose, 3 times daily, starting from day 2 after enrollment; Week 2: oral 3 capsules per dose, 3 times daily; Weeks 3‐8: oral 4 capsules per dose, 3 times daily; all doses taken with meals or after meals. After 8 weeks of treatment, if the investigator judges the subject to benefit, it is recommended to continue taking the medication up to 24 weeks.;Control group:Control group: Placebo + basic treatment. The placebo used in the placebo group is made to be identical to pirfenidone capsules in appearance, packaging, and odor.; CONDITION: Non small cell lung cancer, radiation or immune pneumonia PRIMARY OUTCOME: The percentage of patients hospitalized or who died for any reason related to acute lung exacerbation at 24 weeks; SECONDARY OUTCOME: The changes in DLCO%, FVC and FEV1 at week 24 compared with the baseline;The changes in CT scores at week 24 compared with the baseline;The changes in the classification of cough, dyspnea and fever symptoms at week 24 compared with the baseline;Progression‐free survival (PFS) of patients with different cancer types;The overall survival period of patients classified by cancer type; INCLUSION CRITERIA: 1. Age range: 18‐75 years old (including 18 and 75 years old); 2. Pathologically diagnosed non‐small cell lung cancer, small cell lung cancer, or esophageal cancer patients; 3. Whole body condition assessment, ECOG 0‐2; 4. Those with an expected survival period of more than 6 months; 5. Clinically diagnosed grade 2‐3 radiation‐induced or immune induced lung injury; 6. The duration of radiation‐induced or immune induced lung injury is less than 2 months; 7. The functional level of major organs meets the following standards; 8. The blood routine examination standards must meet the following criteria: ANC >= 3.0 X10^9/L, PLT >= 100 X10^9/L, Hb >= 90 g/L; 9. Biochemical tests must meet the following standards: TBIL, BUN, and Cr <= 1.5 XULN, ALT and AST <= 2.0 XULN; 10. The subjects voluntarily joined this study and signed an informed consent form.